Finance Express . . 95 financings in the health care sector in November! JD.com Health $1.36 billion, the highest in the month!

JD.com Health completed a $1.36 billion (about 9 billion yuan) strategic financing this month, the largest amount disclosed this month.
. The largest amount in the pharmaceutical sector this month came from Jiangsu Ruike Biotechnology Co., Ltd. ("Rico Bio"), which announced on November 12 that it had completed a round B financing to raise more than RMB1.5 billion.
. 95 cases were financed in the field of health care in November, with a disclosed amount of about 25.855 billion yuan, 46 financing cases of more than 100 million yuan, and a disclosure amount of about 25.333 billion yuan.
November financing profile 1. The number and scale of November medical and health sector financing 95 cases, the disclosure amount of about 25.855 billion yuan, the financing amount of more than 100 million yuan of 46 cases, the total financing amount of about 25.333 billion yuan, the total amount of financing of more than 100 million yuan accounted for 97.98 percent of the total financing scale in the current month.
disclosed this month that JD.com had completed $1.36 billion (about 9 billion yuan) in strategic financing, with investors including GIC Singapore Government Investment Corporation, Gao Yan Capital, BlackRock, Tiger Global Management, Qingchi Capital and China's state-owned enterprise restructuring fund.
the second largest financing project this month is: Jiangsu Ruike Biotechnology Co., Ltd.
Bio officially announced the completion of round B financing, financing amounting to more than 1.5 billion yuan.
This round of financing by Junlian Capital, Jifeng Capital, Sequoia Capital, Temasek Xiangfeng, Haitong Kaiyuan, Keystone Capital, Yuansheng Venture Capital, Qingsong Capital, Everbright Holdings and other well-known domestic and foreign venture capital institutions jointly invested.
Life Capital as the main financial advisor for this round of financing, helping the company to lock in major lead investors and major financing shares in a very short period of time.
the third largest financing project this month is: Deji Pharmaceuticals (Wuxi) Co., Ltd.
, a global biotech company focused on developing and commercializing precision therapy drugs, recently announced the completion of a $200 million round of financing.
investors in the current round of financing include Boyu Capital, Latitude China, Sequoia China, Temasek Temasek and Pharmaceutical Mingkang Venture Capital Fund.
will be used to support Deji Pharmaceuticals in developing its portfolio of product pipelines to treat cancer and immune diseases.
table 1: November medical and health industry financing scale TOP10 project data source: Firestone creation database 2. Financing phase distribution in November, the number of domestic health industry financing projects concentrated in the A, B stage (including Pre-A round, Pre-A plus round, A Round, A-plus, B-round, B-round) totaled 42 cases, accounting for about 44.21% of the total number of projects, equity financing and strategic financing of 19 and 12, respectively, each accounting for about 20% and 14.74% of the total number of projects.
amount of strategic financing in each round of financing amounted to 10,818 million yuan, accounting for about 41.84 percent of the total amount this month. In the
sub-sector financing segment, the number of financing projects in the pharmaceutical sector was 26, accounting for 27.37 percent of the total number of financing projects, 24 financing projects in the medical device sector, accounting for 25.26 percent of the total number of financing projects, 15 projects in industrial services financing, accounting for 15.79 percent of the total number of financing projects, and the number of financing projects in the medical services sector was 9, accounting for 9.47 percent of the total financing projects.
this month, the amount of financing in the medical services sector was 9.137 billion yuan, accounting for 35.34 percent of the total financing amount.
1. The largest amount of money in the pharmaceutical sector this month came from Jiangsu Ruike Biotech Co., Ltd., which announced on November 12 that it had completed a round B financing to raise more than Rmb1.5bn.
This round by Junlian Capital, Jifeng Capital, Sequoia Capital, Temasek Xiangfeng, Haitong Kaiyuan, Keystone Capital, Yuansheng Venture Capital, Qingsong Capital, Everbright Holdings and other well-known domestic and foreign venture capital institutions jointly invested.
Life Capital as the main financial advisor for this round of financing, assisting the company in a very short period of time to lock in the major lead investors and major financing shares.
This financing will focus on the company's key varieties industrialization base construction, HPV nine-price vaccine, restructuring of new crown vaccine and other products clinical trials, follow-up product pipeline research and development and core technology platform construction and international expansion of business promotion.
table 2: November pharmaceutical sector financing TOP10 project data source: Firestone Creation Database 2. The largest amount of financing in the medical device field this month is: Shanghai Xiamen Biosciences Co., Ltd. (Cytek Biosciences Inc., referred to as "Xiatai Bio").
announced on November 5th that it had completed a $120 million round of D financing.
this round of financing is jointly led by RA Capital and Sogo Capital, and OrbiMed, Jifeng Capital and Kunlun Capital are also involved in this round of financing.
addition, RA Capital and High Capital have joined Cytek's board of directors.
financing will be used to expand its global infrastructure, sustain growth and deliver its technology platform to provide scalable support in key research areas such as immunotherapy, immuno-oncology and infectious diseases such as COVID-19.
table 3: November medical device sector billion yuan scale financing data source: Firestone creation database financing geographical distribution profile in November, financing projects concentrated in Shanghai, Jiangsu, Beijing, Zhejiang, the total number of financing projects 69, accounting for about 72.6%.
Of these, 22 were financing projects in Shanghai, accounting for 23.16% of the total number of financing projects in the month, 19 financing projects in Jiangsu, accounting for 20% of the total number of financing projects in the current month, 16 financing projects in Beijing, accounting for 16.84% of the total number of financing projects in the current month, and 12 financing projects in Zhejiang, accounting for 12.63% of the total number of financing projects in the month.
beijing this month amounted to 12.255 billion yuan, accounting for 47.40% of the total financing.
, Beijing disclosed the amount of financing and the amount of financing occupied the first and third, respectively, including a number of heavy-weight financing incidents.
Beijing JD.com Health Co., Ltd. completed a $1.36 billion (rmb9 billion) strategic financing on November 26, with investors including GIC Singapore Government Investment Corporation, Gao Yan Capital, BlackRock, Tiger Global Management, Qingchi Capital and China State-owned Enterprise Structural Adjustment Fund.
In the past year or so, JD.com has become a healthy outbreak period, expanding from consultation services to health management services, from independent operations to leapfrog into JD.com Group hatched the third unicorn, from pharmaceutical e-commerce to complete the complete "Internet plus medical health" ecosystem layout, its energy is from the previous accumulation of up to 5 years.
in the process, JD.com health also completed two rounds of huge financing, favored by star investment institutions such as Gaosheng Capital, and set a record of more than $900 million in single financing.
the future, JD.com health will continue to explore other opportunities to empower upstream companies in the healthcare value chain.
On August 20 this year, Waterdrop announced the completion of a $230 million round of D-round financing, jointly led by Swiss Re and Tencent, followed by old shareholders such as IDG Capital, LightIng Global Fund and Salman Capital.
at the same time, there were reports that the round of financing after the water drop company valuation reached 4 billion to 6 billion U.S. dollars.
water drop company plans an IPO in the first quarter of next year, valued at $6 billion.
the 300m yuan valuation disclosed by the company at the time of the angel round's financing, its valuation has increased nearly 130-fold in four years.
business, water drop company including water drop chip, water drop mutual aid and water drop insurance, this year the platform-wide independent paid users of nearly 330 million people, of which the insurance business cumulatively protected more than 100 million users, to protect the number of families nearly 60 million.
, as its main source of revenue, water drop insurance mall in the first half of this year completed the signing of nearly 6 billion premiums, close to the 2019 full-year annualized premium amount, and in July completed another 1.5 billion.
, general manager of China Water Drop Insurance Mall, has said that this year's paid premiums are expected to reach 6 billion yuan, up 300% year-on-year.
the morning of November 24, 2020, Tencent Holdings, which raised $230 million in August, is considering an IPO with a target valuation of about $4 billion.
will use the investment to expand its online platform and support technology development.
the money will also help water droplets in the insurance technology industry, enhance the competitiveness of the Ant Group.
tencent has been a strong investor in the development of water drop companies.
started investing in Water Drops in Angel Wheel, and has since led rounds A and B financing, and continues to support the C and D rounds of financing, according to public information released by the company.
Table 4: Data on the financing of 100 million yuan in Beijing's medical and health industry in November Source: Firestone Creation Database 2. 22 financing projects in Shanghai this month, 5 of which disclosed the amount of financing, with a total disclosure of about 3.219 billion yuan.
,000-year-old CAR-T cell drug research and development company Koji Bio announced the completion of a $186 million round of C financing.
this financing by Zhengsing Valley Capital, Lilly Asia Fund, Jade Capital, Xia Wei Capital and other investment, the existing shareholders of China Southern Ventures continue to pursue investment.
Kozi Bio has obtained the first registered clinical license for CAR-T cell therapy for GPC3-positive solid tumors, the first CLDN18.2 CAR-T cell drug clinical trial license and two clinical trial licenses for hematoma CAR-T cell drugs, and a number of products have been identified by the FDA, european EMA "orphan drug".
Zonghai Li, founder, chairman, chief executive officer and chief scientist of Koji Bio, said the round of financing will greatly promote the internationalization of Koji Bio, and bring it to market as soon as possible for the benefit of cancer patients worldwide.
table 5: November Shanghai medical and health industry billion yuan scale financing data source: Firestone creation database investment institutions in November active in the medical and health industry investment institutions TOP3: Gaosheng Ventures (7), Yuansheng Ventures (7), the former jellyfish fund (3).
Among them, Gaosheng Ventures, Yuansheng Ventures and the former jellyfish fund jointly invested in Insein Bio, Yuansheng Ventures and the former jellyfish fund jointly invested in the project Lancet robot.
For specific investment projects, see table below: Table 6: November active investment institutions invested project data sources: Firestone Creation Database Close November financing cases and financing amount increased month-on-month in October, compared with the vast majority of other industries affected by the new crown epidemic, investment in the health sector in the current year is still in a steady climbing stage.
the sectors with the high number of financing projects this month are: pharmaceuticals (26, or 27.37%), medical devices (24, 25.26%), industrial services (15, 15.79%), and medical services (9, 9.47%).
november, the total number of financing projects was concentrated in Shanghai (22), Jiangsu (19), Beijing (16) and Zhejiang (12), accounting for about 72.63 percent of the total number of financing projects.
, Shanghai and Jiangsu have always been the key areas to absorb investment, and Zhejiang, which has a number of head enterprises, is also a key area of capital concern.
。